Bromazepam: Difference between revisions

	WikiDoc Resources for Bromazepam
Articles
Most recent articles on Bromazepam Most cited articles on Bromazepam Review articles on Bromazepam Articles on Bromazepam in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Bromazepam Images of Bromazepam Photos of Bromazepam Podcasts & MP3s on Bromazepam Videos on Bromazepam
Evidence Based Medicine
Cochrane Collaboration on Bromazepam Bandolier on Bromazepam TRIP on Bromazepam
Clinical Trials
Ongoing Trials on Bromazepam at Clinical Trials.gov Trial results on Bromazepam Clinical Trials on Bromazepam at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Bromazepam NICE Guidance on Bromazepam NHS PRODIGY Guidance FDA on Bromazepam CDC on Bromazepam
Books
Books on Bromazepam
News
Bromazepam in the news Be alerted to news on Bromazepam News trends on Bromazepam
Commentary
Blogs on Bromazepam
Definitions
Definitions of Bromazepam
Patient Resources / Community
Patient resources on Bromazepam Discussion groups on Bromazepam Patient Handouts on Bromazepam Directions to Hospitals Treating Bromazepam Risk calculators and risk factors for Bromazepam
Healthcare Provider Resources
Symptoms of Bromazepam Causes & Risk Factors for Bromazepam Diagnostic studies for Bromazepam Treatment of Bromazepam
Continuing Medical Education (CME)
CME Programs on Bromazepam
International
Bromazepam en Espanol Bromazepam en Francais
Business
Bromazepam in the Marketplace Patents on Bromazepam
Experimental / Informatics
List of terms related to Bromazepam

Bromazepam
Clinical data
Pregnancy; category	D (USA);
Routes of; administration	Oral
ATC code	N05BA08 (WHO) ;
Legal status
Legal status	Schedule IV(US);
Pharmacokinetic data
Bioavailability	84%
Metabolism	Hepatic
Elimination half-life	10-20 hours
Excretion	Renal
Identifiers
	IUPAC name 9-bromo-6-pyridin-2-yl-; 2,5-diazabicyclo[5.4.0]undeca-5,8,10,12-tetraen-3-one;
CAS Number	1812-30-2;
PubChem CID	2441;
DrugBank	?;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C14H10BrN3O
Molar mass	316.2

VisualWikitext

Revision as of 18:54, 27 September 2011

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Bromazepam (marketed under brand names Calmepam, Compendium, Creosedin, Durazanil, Lectopam, Lexaurin, Lexilium, Lexomil, Lexotan, Lexotanil, Normoc, Novepam, Somalium)^[1] is a drug which is a benzodiazepine derivative. It has sedative, hypnotic, anxiolytic and skeletal muscle relaxant properties.

Pharmacology

Its molecular structure is composed of a diazepine connected to a benzene ring and a pyridine ring, the benzene ring having a bromine atom attached to it.^[2] It is a 1,4-benzodiazepine, which means that the nitrogens on the seven-sided diazepine ring are in the 1 and 4 positions.

Bromazepam binds to the GABA receptor GABA_A, causing a conformational change and increasing inhibitory effects of GABA. Other neurotransmitters are not influenced. Bromazepam is intermediate-short acting benzodiazepine and is lipophilic, is metabolised hepatically via oxidative pathways.^[3] It does not possess any antidepressant qualities. Bromazepam shares with other benzodiazepines the risk of abuse, misuse, psychological and/or physical dependence. According to many psychiatric experts Bromazepam has a greater abuse potential than other benzodiazepines because of fast resorption and rapid onset of action. Due to its relatively short halflife and duration of action (8 to 12 hours), withdrawal symptoms may be more severe and more frequently encountered than with long acting benzodiazepines.

Bromazepam is reported to be metabolized by a hepatic enzyme belonging to the Cytochrome P450 family of enzymes. In 2003, a team led by Dr. Oda Manami at Oita Medical University reported that CYP3A4 was not the responsible enzyme, seeing as itraconazole, a known inhibitor of CYP3A4, did not effect its metabolism.^[4] In 1995, J. van Harten at Solvay Duphar B.V.'s Department of Clinical Pharmacology in Weesp reported that fluvoxamine, which is a potent inhibitor of CYP1A2, a less potent CYP3A4 inhibitor, and a negligible inhibitor of CYP2D6, does inhibit its metabolism.^[5]

The active metabolite of bromazepam is hydroxybromazepam.

Indications

Short-term treatment of insomnia
Short-term treatment of anxiety or panic attacks, if a benzodiazepine is required
Alleviation of the symptoms of alcohol- and opiate-withdrawal, under close clinical supervision

Availability

Bromazepam is available as a generic in Belgium(as Lexotan), Bosnia, Bulgaria, Canada, Chile, Denmark (as Bromam), France, Germany,Israel (Lenitin, by Teva), Italy, Kosovo, Macedonia, The Netherlands (as Lexotanil), Poland, Portugal and Switzerland.

It is also available as Lexotanil in Bangladesh, Colombia, Greece, Pakistan, United Arab Emirates and Venezuela.

It is available as Leoxotan and Somalium in Australia, Brazil, Portugal and Singapore.

It is available as Lexilium in Macedonia and Serbia.

Dosage

Usually, 3mg to 6mg at bedtime, with additional 1.5mg to 3mg during the next day if needed. Malnourished patients, patients with compromised cardiovascular, liver or renal function, and elderly patients should receive lower doses. In hospitalized patients with severe agitation and/or anxiety, daily doses of up to 24mg have been given and tolerated for a limited period of time. A 3mg dose of bromazepam is equivalent to a 5mg dose of diazepam.

Side-effects

All common side-effects of benzodiazepines have been noted. Consult the article under Diazepam. Euphoria, leading to a high abuse potential, is quite often reported.

Up to 30% treated on a long-term basis develop a form of dependence known as 'low-dose-dependence', i.e. these patients do not need increasing doses to experience the feeling of 'well-being' caused by the drug.

Leukopenia and liver-damage of the cholostatic type with or without jaundice (icterus) have additionally been seen; the original manufacturer Roche recommends regular laboratory examinations to be performed routinely.

Ambulatory patients should be warned that Bromazepam may impair the ability to drive vehicles and to operate machinery. The impairment is worsened by consumption of alcohol, because both act as central nervous system depressants. During the course of therapy, tolerance to the sedative effect usually develops.

Contraindications

The general contraindications for benzodiazepines apply. Consult the section under Diazepam.

Special Populations

In 1987, a team of scientists lead by Ochs reported that the elimination half-life, peak serum concentration, and serum free fraction are significantly elevated and the oral clearance and volume of distribution significantly lowered in elderly subjects.^[6] The clinical consequence is that the elderly should be treated with lower doses than younger patients.

Legal Status

Bromazepam is a Schedule IV drug under the Convention on Psychotropic Substances.^[7]

References

↑ PubChem Substance: Bromazepam National Center of Biotechnology Information.
↑ Bromazepam Eutimia.com - Salud Mental. © 1999-2002.
↑ Oelschläger H. (4). "[Chemical and pharmacologic aspects of benzodiazepines]". Schweiz Rundsch Med Prax. 78 (27–28): 766–72. PMID 2570451. Unknown parameter |month= ignored (help); Check date values in: |date=, |year= / |date= mismatch (help)
↑ Oda M, Kotegawa T, Tsutsumi K, Ohtani Y, Kuwatani K, Nakano S. "The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers." European Journal of Clinical Pharmacology. 2003 Nov;59(8-9):615-9. Epub 2003 Sep 27. PMID 14517708 English Fulltext (registration required) Japanese Fulltext (PDF, no registration)
↑ van Harten J. "Overview of the pharmacokinetics of fluvoxamine." Clinical Pharmacokinetics. 1995;29 Suppl 1:1-9. PMID 8846617
↑ Ochs HR, Greenblatt DJ, Friedman H, Burstein ES, Locniskar A, Harmatz JS, Shader RI. "Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol." Clinical Pharmacology & Therapeutics. 1987 May;41(5):562-70. PMID 2882883
↑ List of psychotropic substances under international control (PDF). International Narcotics Control Board.

External links

Inchem - Bromazepam

Template:Benzodiazepines Template:SIB

Template:WS

[brandnames-1] PubChem Substance: Bromazepam National Center of Biotechnology Information.

[bromazepamstructure-2] Bromazepam Eutimia.com - Salud Mental. © 1999-2002.

[3] Oelschläger H. (4). "[Chemical and pharmacologic aspects of benzodiazepines]". Schweiz Rundsch Med Prax. 78 (27–28): 766–72. PMID 2570451. Unknown parameter |month= ignored (help); Check date values in: |date=, |year= / |date= mismatch (help)

[itraconazole-4] Oda M, Kotegawa T, Tsutsumi K, Ohtani Y, Kuwatani K, Nakano S. "The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers." European Journal of Clinical Pharmacology. 2003 Nov;59(8-9):615-9. Epub 2003 Sep 27. PMID 14517708 English Fulltext (registration required) Japanese Fulltext (PDF, no registration)

[fluvoxamine-5] van Harten J. "Overview of the pharmacokinetics of fluvoxamine." Clinical Pharmacokinetics. 1995;29 Suppl 1:1-9. PMID 8846617

[bromazepamold-6] Ochs HR, Greenblatt DJ, Friedman H, Burstein ES, Locniskar A, Harmatz JS, Shader RI. "Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol." Clinical Pharmacology & Therapeutics. 1987 May;41(5):562-70. PMID 2882883

[schedule4-7] List of psychotropic substances under international control (PDF). International Narcotics Control Board.

[1]

[2]

[3]

[4]

[5]

[6]

[7]